The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients
Sirolimus ( SRL ) is a promising alternative to calcineurin inhibitors, such as tacrolimus ( TAC ), in kidney transplant recipients ( KTR s), but the immunological benefits of conversion from calcineurin inhibitors to SRL are not fully investigated. In the present study, we evaluated the effect of conversion from TAC to SRL on the T helper type 17/regulatory T (Th17/Treg) axis in three separate studies. First, the effect of SRL on the Th17/Treg axis was evaluated in vitro using peripheral blood mononuclear cells ( PBMC s). Second, the effect of conversion from TAC to SRL on the Th17/Treg axis was studied in KTR s. Finally, the effect of SRL on CD 8 + Treg cells was evaluated. In vitro analysis of PBMC s isolated from KTR s showed that SRL suppressed Th17 cell differentiation but TAC did not. Conversion from TAC to SRL markedly decreased the number of effector memory CD 8 + T cells and significantly increased the proportion of CD 4 + and CD 8 + Treg cells compared with TAC in KTR s. SRL treatment induced the CD 8 + Treg cells, and these cells inhibited the proliferation of allogeneic CD 4 + T cells and Th17 cells. In conclusion, conversion from TAC to SRL favourably regulates Th17 and Treg cell differentiation in KTR s. These findings provide a rationale for conversion from TAC to SRL in KTR s..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:144 |
|---|---|
| Enthalten in: |
Immunology - 144(2015), 1, Seite 68-78 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Kyoung Woon [VerfasserIn] |
|---|
| Links: |
Volltext |
|---|
| RVK: |
|---|
| doi: |
10.1111/imm.12351 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1964045134 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1964045134 | ||
| 003 | DE-627 | ||
| 005 | 20230516124130.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1111/imm.12351 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1964045134 | ||
| 035 | |a (DE-599)GBVOLC1964045134 | ||
| 035 | |a (PRQ)p1741-7034630fca902c8263e6422c1349078678193d7551b52b49aa52be1f0d2a12cd0 | ||
| 035 | |a (KEY)0025421520150000144000100068effectofmammaliantargetofrapamycininhibitiononthel | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a XA 10000 |q AVZ |2 rvk | ||
| 084 | |a 44.45 |2 bkl | ||
| 100 | 1 | |a Kim, Kyoung Woon |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Sirolimus ( SRL ) is a promising alternative to calcineurin inhibitors, such as tacrolimus ( TAC ), in kidney transplant recipients ( KTR s), but the immunological benefits of conversion from calcineurin inhibitors to SRL are not fully investigated. In the present study, we evaluated the effect of conversion from TAC to SRL on the T helper type 17/regulatory T (Th17/Treg) axis in three separate studies. First, the effect of SRL on the Th17/Treg axis was evaluated in vitro using peripheral blood mononuclear cells ( PBMC s). Second, the effect of conversion from TAC to SRL on the Th17/Treg axis was studied in KTR s. Finally, the effect of SRL on CD 8 + Treg cells was evaluated. In vitro analysis of PBMC s isolated from KTR s showed that SRL suppressed Th17 cell differentiation but TAC did not. Conversion from TAC to SRL markedly decreased the number of effector memory CD 8 + T cells and significantly increased the proportion of CD 4 + and CD 8 + Treg cells compared with TAC in KTR s. SRL treatment induced the CD 8 + Treg cells, and these cells inhibited the proliferation of allogeneic CD 4 + T cells and Th17 cells. In conclusion, conversion from TAC to SRL favourably regulates Th17 and Treg cell differentiation in KTR s. These findings provide a rationale for conversion from TAC to SRL in KTR s. | ||
| 540 | |a Nutzungsrecht: © 2014 John Wiley & Sons Ltd | ||
| 540 | |a © 2014 John Wiley & Sons Ltd. | ||
| 650 | 4 | |a cytokines | |
| 650 | 4 | |a mTOR | |
| 650 | 4 | |a regulatory T cells | |
| 650 | 4 | |a T cells | |
| 650 | 4 | |a transplantation | |
| 650 | 4 | |a Cell Differentiation - immunology | |
| 650 | 4 | |a Sirolimus - pharmacokinetics | |
| 650 | 4 | |a CD8-Positive T-Lymphocytes - immunology | |
| 650 | 4 | |a Calcineurin Inhibitors - pharmacokinetics | |
| 650 | 4 | |a Tacrolimus - administration & dosage | |
| 650 | 4 | |a Th17 Cells - cytology | |
| 650 | 4 | |a T-Lymphocytes, Regulatory - immunology | |
| 650 | 4 | |a Tacrolimus - pharmacokinetics | |
| 650 | 4 | |a Th17 Cells - immunology | |
| 650 | 4 | |a TOR Serine-Threonine Kinases - immunology | |
| 650 | 4 | |a TOR Serine-Threonine Kinases - antagonists & inhibitors | |
| 650 | 4 | |a CD8-Positive T-Lymphocytes - cytology | |
| 650 | 4 | |a T-Lymphocytes, Regulatory - cytology | |
| 650 | 4 | |a Cell Differentiation - drug effects | |
| 650 | 4 | |a Calcineurin Inhibitors - administration & dosage | |
| 650 | 4 | |a Transplants & implants | |
| 650 | 4 | |a T cell receptors | |
| 700 | 1 | |a Chung, Byung Ha |4 oth | |
| 700 | 1 | |a Kim, Bo‐Mi |4 oth | |
| 700 | 1 | |a Cho, Mi‐La |4 oth | |
| 700 | 1 | |a Yang, Chul Woo |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Immunology |d Oxford [u.a.] : Wiley-Blackwell, 1958 |g 144(2015), 1, Seite 68-78 |w (DE-627)129269271 |w (DE-600)80124-0 |w (DE-576)01445971X |x 0019-2805 |7 nnns |
| 773 | 1 | 8 | |g volume:144 |g year:2015 |g number:1 |g pages:68-78 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1111/imm.12351 |3 Volltext |
| 856 | 4 | 2 | |u http://onlinelibrary.wiley.com/doi/10.1111/imm.12351/abstract |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/24974886 |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1633977826 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | r | v | |a XA 10000 |
| 936 | b | k | |a 44.45 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 144 |j 2015 |e 1 |h 68-78 | ||